The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy.
Siarhei Alexander DabravolskiNikolay K SadykhovAndrey G KartuesovEvgeny E BorisovVasily Nikolaevich SukhorukovAlexander N OrekhovPublished in: International journal of molecular sciences (2022)
Diabetic cardiomyopathy (DCM) is defined as the presence in diabetic patients of abnormal cardiac structure and performance (such as left ventricular hypertrophy, fibrosis, and arrhythmia) in the absence of other cardiac risk factors (such as hypertension or coronary artery disease). Although the pathogenesis of DCM remains unclear currently, mitochondrial structural and functional dysfunctions are recognised as a central player in the DCM development. In this review, we focus on the role of mitochondrial dynamics, biogenesis and mitophagy, Ca 2+ metabolism and bioenergetics in the DCM development and progression. Based on the crucial role of mitochondria in DCM, application of mitochondria-targeting therapies could be effective strategies to slow down the progression of the disease.
Keyphrases
- left ventricular
- oxidative stress
- heart failure
- coronary artery disease
- risk factors
- type diabetes
- cell death
- blood pressure
- wound healing
- acute myocardial infarction
- reactive oxygen species
- hypertrophic cardiomyopathy
- percutaneous coronary intervention
- endoplasmic reticulum
- aortic stenosis
- cardiac resynchronization therapy
- cardiovascular disease
- mitral valve
- left atrial
- coronary artery bypass grafting
- cancer therapy
- nlrp inflammasome
- arterial hypertension